LY 3113593Alternative Names: LY3113593
Latest Information Update: 09 Feb 2017
At a glance
- Originator Eli Lilly
- Mechanism of Action Bone morphogenetic protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Anaemia
Most Recent Events
- 22 Jun 2016 Eli Lilly completes a phase I trial for Anaemia (In patients with chronic kidney disease) in USA (IV) (NCT02604160)
- 25 Jan 2016 Phase-II clinical trials in Anaemia in USA (Parenteral) before January 2016
- 01 Aug 2015 Eli Lilly completes a phase I trial in Anaemia in USA (NCT02144285)